DDInter1296 DDInter105
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Nintedanib {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Nintedanib may lead to a major life threatening interaction when taken with Lomitapide
Nintedanib may lead to a major life threatening interaction when taken with Lumacaftor